crenolanib

Crenolanib is an oral targeted therapy drug that acts as a tyrosine kinase inhibitor. It is primarily used in the treatment of certain types of cancer. Specifically, crenolanib has been investigated for its efficacy in patients with advanced gastrointestinal stromal tumors (GIST) that have become resistant to or cannot tolerate other standard therapies. It is also being studied for its potential in treating other malignancies.

The mechanism of action for crenolanib involves blocking the activity of specific kinases, particularly platelet-derived growth factor receptor (PDGFR) alpha and beta, and KIT. These kinases play crucial roles in cell growth and division. By inhibiting these pathways, crenolanib can slow or stop the growth of cancer cells that rely on these signals.

Clinical trials have been conducted to evaluate the safety and effectiveness of crenolanib. These studies have aimed to determine optimal dosing, identify side effects, and assess its benefit in prolonging progression-free survival and overall survival in patients with GIST and other cancers. Common side effects observed in clinical trials can include fatigue, nausea, diarrhea, abdominal pain, and skin rash. As with any potent medication, its use requires careful monitoring by a healthcare professional. Crenolanib represents an important option for patients with specific genetic mutations in their tumors that make them susceptible to this type of targeted therapy.